Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"
Jump to navigation
Jump to search
m |
m |
||
| Line 29: | Line 29: | ||
[[Category:Antimetabolites]] | [[Category:Antimetabolites]] | ||
[[Category:Deoxycytidine analogues]] | [[Category:Deoxycytidine analogues]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
Revision as of 00:17, 23 September 2023
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. [1][2][3]
Route: IV
Extravasation: no information
Disease for which it is established
History of changes in FDA indication
- 2017-08-03: Granted FDA regular approval for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. (Based on CLTR0310-301)
History of changes in EMA indication
- 2018-08-23: Initial authorization
Patient Information
Also known as
- Code name: CPX-351
- Brand name: Vyxeos, Vyxeos liposomal